Cubist Pharmaceuticals to Acquire Adolor for $190 Million

Cubist Pharmaceuticals Inc. (CBST), the maker of the antibiotic Cubicin, said it will acquire Adolor Corp. (ADLR) for $190 million in cash to gain a constipation drug. Adolor shares rose the most in almost 11 years.

Adolor investors will receive $4.25 a share as well as a so-called contingent payment right of as much as $4.50 a share if certain regulatory approvals are met, Lexington, Massachusetts-based Cubist said in a statement today. The acquisition is valued at as much as $415 million, net of Adolor’s third-quarter cash balance, the companies said.

Cubist will gain Adolor’s Entereg constipation medicine, which generated $25.4 million for the Exton, Pennsylvania-based company last year. Adolor is also testing a treatment for opioid-induced constipation, and the contingent payment right is subject to that drug’s approval and commercialization.

“This transaction is an excellent strategic fit for Cubist and the latest milestone in what has been a transformational year for the company,” Michael Bonney, Cubist’s chief executive officer, said in the statement.

Adolor more than doubled to $4.67 at 4 p.m. New York time, the biggest jump since the company first sold shares to the public in November 2000. Cubist fell 1.9 percent to $39.60.

Both companies’ boards unanimously approved the deal, which is expected to close in the fourth quarter of this year, according to the statement. Morgan Stanley acted as financial adviser to Cubist, while Ropes & Gray LLP provided legal counsel. Stifel Nicolaus Weisel was financial adviser to Adolor and Dechert LLP served as legal counsel.

To contact the reporter on this story: Anna Edney in Washington at

To contact the editor responsible for this story: Adriel Bettelheim at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.